Pipeline — registered trials by phase
Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies
— · Parkinson's Disease · Completed · est. 2023-07-18
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
— · Schizophrenia, Schizoaffective Disorder, Bipolar Disorder · Recruiting · est. 2028-06
The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine
— · Tardive Dyskinesia (TD) · Completed · est. 2019-04-03
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
— · Schizophrenia, Schizoaffective Disorder, Bipolar Disorder · Completed · est. 2024-12-27
Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia
— · Tardive Dyskinesia (TD) · Completed · est. 2019-12-23
Opicapone Treatment Initiation Open-Label Study
— · Parkinson Disease · Completed · est. 2022-08-04
Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects
— · Healthy Volunteers · Completed · est. 2019-06-09
A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants
— · Healthy Volunteers · Completed · est. 2018-12-11
A Two-part, Study to Compare the Pharmacokinetics and Dose Proportionality of up to 6 Chronocort Formulations
— · Adrenal Insufficiency, Congenital Adrenal Hyperplasia · Completed · est. 2012-04
Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency
— · Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects · Completed · est. 2013-12
A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation
— · Healthy Volunteers · Completed · est. 2017-05-19
Comparison of Pharmacokinetics of Infacort® Versus Immediate-release Hydrocortisone
— · Healthy Subjects · Completed · est. 2013-09
Effect of Slow Release Hydrocortisone on Fed & Fasting Volunteers; Immediate Release on Fasting Only
— · Healthy · Completed · est. 2015-03
Bioavailability of Infacort When Administered Onto Food Compared to Direct Oral Administration
— · Adrenal Insufficiency · Completed · est. 2017-07-26
Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study
— · Healthy Volunteers, Schizophrenia · Completed · est. 2019-09-22
TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants
— · Depressive Disorder · Completed · est. 2017-09-11
An Investigational Study of Hydrocortisone
— · Adrenal Insufficiency · Completed · est. 2014-11
Study to Compare DITEST to Testosterone Undecanoate in Adult Men With Hypogonadism
— · Male Hypogonadism · Completed · est. 2018-10-04
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants
— · Healthy · Completed · est. 2018-09-09
A Study of Infacort® Versus Cortef® in Healthy Adult Male and Female Subjects
— · Adrenal Insufficiency · Completed · est. 2018-07-13
VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)
— · Parkinson's Disease · Completed · est. 2024-10-30
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.
— · Parkinson Disease · Completed · est. 2018-07-02
Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects
— · Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects · Completed · est. 2013-08
A Study to Assess Absolute Bioavailability (ABA) of TAK-831 and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of [14C]TAK-831 in Male Healthy Participants
— · Healthy Volunteers · Completed · est. 2020-04-04
An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone
— · Congenital Adrenal Hyperplasia, Adrenal Insufficiency · Completed · est. 2010-04
Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome
— · Tourette Syndrome · Completed · est. 2015-11
Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer
— · Breast Cancer, Kidney Cancer, Lung Cancer · Completed · est. 2003-05
Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease
— · Idiopathic Parkinson's Disease, Parkinson's Disease, Basal Ganglia Disease · Completed · est. 2021-08-10
A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)
— · Healthy Volunteers · Completed · est. 2017-05-30
A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)
— · Healthy Volunteers · Completed · est. 2019-05-15
A Study of Chronocort® Versus Cortef ® in Healthy Adult Male Subjects
— · Adrenal Insufficiency · Completed · est. 2018-04-20
NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme
— · Brain and Central Nervous System Tumors · Completed · est. 2002-09
A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia
— · Schizophrenia · Completed · est. 2020-12-21
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia
— · CAH - Congenital Adrenal Hyperplasia · Completed · est. 2020-04-07
Safety, Efficacy, and Tolerability of NBI-827104 for the Treatment of Essential Tremor
— · Essential Tremor · Completed · est. 2022-05-25
A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures
— · Focal Onset Seizure, Focal Onset Epilepsy · Completed · est. 2023-08-21
Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal Insufficiency
— · Primary Adrenal Insufficiency · Completed · est. 2023-10-18
Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH
— · Endocrine Disease, Adrenal Insufficiency, Congenital Adrenal Hyperplasia · Completed · est. 2013-12
Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome
— · Tourette Syndrome · Completed · est. 2017-04-14
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
— · Tardive Dyskinesia · Completed · est. 2013-09
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH)
— · Congenital Adrenal Hyperplasia · Not Yet Recruiting · est. 2028-03-16
NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia
— · Tardive Dyskinesia · Completed · est. 2013-12
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep
— · Epileptic Encephalopathy, Continuous Spike and Wave During Sleep · Completed · est. 2022-08-08
An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania
— · Bipolar I Disorder, Mania · Recruiting · est. 2028-02
Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
— · Tourette Syndrome · Completed · est. 2017-11-01
Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)
— · Multiple Sclerosis · Completed
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
— · Major Depressive Disorder · Completed · est. 2025-07-25
A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia
— · Schizophrenia · Completed · est. 2020-12-29
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
— · Schizophrenia · Recruiting · est. 2027-08
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia
— · Schizophrenia · Completed · est. 2024-07-10
Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
— · Tourette Syndrome · Completed · est. 2019-07-12
Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)
— · Major Depressive Disorder · Completed · est. 2024-01-10
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
— · Tardive Dyskinesia · Completed · est. 2012-02
Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia
— · Friedreich Ataxia · Completed · est. 2018-12-27
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 (Crinecerfont) in Pediatric Participants With Congenital Adrenal Hyperplasia
— · CAH - Congenital Adrenal Hyperplasia · Completed · est. 2021-07-02
Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a Background Acetylcholinesterase Inhibitor
— · Alzheimer's Disease · Not Yet Recruiting · est. 2028-05
Treatment of Adrenal Insufficiency in Children
— · Adrenal Insufficiency · Completed · est. 2016-07
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
— · Congenital Adrenal Hyperplasia · Active Not Recruiting · est. 2023-07-19
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
— · Major Depressive Disorder · Recruiting · est. 2027-07
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
— · Major Depressive Disorder · Recruiting · est. 2029-05
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
— · Schizophrenia · Completed · est. 2025-02-04
A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH
— · Congenital Adrenal Hyperplasia · Completed · est. 2022-07-13
Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease
— · Chorea, Huntington · Completed · est. 2021-10-15
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
— · Chorea, Huntington · Completed · est. 2025-11-05
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
— · Major Depressive Disorder · Recruiting · est. 2027-07
Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia
— · Tardive Dyskinesia · Completed · est. 2017-03
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
— · Dyskinesia, Cerebral Palsy · Completed · est. 2025-10-16
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
— · Tardive Dyskinesia · Completed · est. 2015-09
Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia
— · Congenital Adrenal Hyperplasia · Completed · est. 2018-07-28
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
— · Schizophrenia · Recruiting · est. 2029-07
Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia
— · Congenital Adrenal Hyperplasia · Completed · est. 2024-02-02
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
— · Congenital Adrenal Hyperplasia · Active Not Recruiting · est. 2023-03-10
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
— · Schizophrenia · Recruiting · est. 2027-11
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
— · Schizophrenia · Recruiting · est. 2027-10
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
— · Schizophrenia · Recruiting · est. 2031-12
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
— · Major Depressive Disorder · Recruiting · est. 2027-07
Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada
— · Chorea, Huntington · Enrolling By Invitation · est. 2028-04
Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
— · Tardive Dyskinesia · Completed · est. 2017-06-30
A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
— · Major Depressive Disorder · Recruiting · est. 2028-07
Extension Study for Patients Entered Into Study Infacort 003
— · Adrenal Insufficiency · Completed · est. 2018-08-10
CrenessityCrinecerfont
IngrezzaValbenazine Tosylate
Ingrezza SprinkleValbenazine Tosylate
Source: ClinicalTrials.gov (trials where Neurocrine is lead sponsor; 92 active or completed) and Drugs@FDA (3 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-09-28Current report (material event)
- S-82026-07-31Employee stock plan
- 8-K/A2026-07-31Current report (amended)
- 10-Q2026-07-31Quarterly report
- 8-K2026-07-30Current report (material event)
- SCHEDULE 13G/A2026-07-27SCHEDULE 13G/A
- 8-K2026-05-28Current report (material event)
- 8-K2026-05-18Current report (material event)
- SC TO-T/A2026-05-18SC TO-T/A
- 10-Q2026-05-05Quarterly report
- 8-K2026-05-05Current report (material event)
- SCHEDULE 13G2026-04-30SCHEDULE 13G
- SC TO-T/A2026-04-29SC TO-T/A
- SC TO-T/A2026-04-28SC TO-T/A
- SC TO-T2026-04-20SC TO-T
- ARS2026-04-15Annual report to holders
- DEFA14A2026-04-15DEFA14A
- DEF 14A2026-04-15Proxy statement
- SC TO-C2026-04-07SC TO-C
- SC TO-C2026-04-06SC TO-C
- SC TO-C2026-04-06SC TO-C
- 8-K2026-04-06Current report (material event)
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- 10-K2026-02-11Annual report
- 8-K2026-02-11Current report (material event)
- SCHEDULE 13G2026-01-21SCHEDULE 13G
- 8-K2025-11-24Current report (material event)
- 10-Q2025-10-28Quarterly report
- 8-K2025-10-28Current report (material event)
- 10-Q2025-07-30Quarterly report
- 8-K2025-07-30Current report (material event)
- 8-K2025-05-30Current report (material event)
- 8-K2025-05-22Current report (material event)
- S-8 POS2025-05-21S-8 POS
- S-8 POS2025-05-21S-8 POS
- S-8 POS2025-05-21S-8 POS
- S-8 POS2025-05-21S-8 POS
- S-8 POS2025-05-21S-8 POS
- S-8 POS2025-05-21S-8 POS
- S-8 POS2025-05-21S-8 POS
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.